Roche: A so-far-ignored asset reports encouraging phase II results
NEUTRAL, Fair Value CHF252 (+5%)
At the American Society of Retina Specialists (ASRS) today will be presented the first results from the phase II MAHALO study which investigates the anti-factor D lampalizumab (RG7417) in so-called geographic atrophy secondary to AMD. Part 1 of the study tested monthly and every other month intravitreal injections whereas part 2 compared the active drug to a sham injection.
Full report available to subscribers
Please contact email@example.com